Tuberculosis Diagnostic Delays and Treatment Outcomes among Patients with COVID-19, California, USA, 2020

Résumé fourni par la source

C alifornia typically reports one quarter of tuber- culosis (TB) cases in the United States and had a 19% case decline during 2020 (1).That decline paralleled national and global observations during the CO-VID-19 pandemic (1,2).Pandemic-related disruptions challenged healthcare systems and TB control programs by diverting staff and other resources (3,4).Pandemic effects on TB diagnostic and care delays in the United States have not been fully described.We aimed to characterize missed opportunities and diagnostic delays, hospitalizations, and treatment outcomes in a subset of patients in California who had TB and COVID-19 during 2020.The California Department of Public Health, Centers for Disease Control and Prevention, and participating local health departments reviewed and approved this activity.This study was conducted consistent with applicable federal and Centers for Disease Control and Prevention policies (Appendix, https://wwwnc.cdc.gov/EID/article/30/1/23-0924-App1.pdf). The StudyUsing surveillance records of TB and COVID-19, we used name-based probabilistic matching to find persons with diagnosed TB and COVID-19 in California (5).We abstracted records for 58 patients who had TB disease diagnosed in 2020 and COVID-19 diagnosed within 120 days and who resided in 6 local health jurisdictions with high TB burdens: Los Angeles, San Diego, Santa Clara, Orange, Alameda, and Sacramento Counties (Figure 1).We captured TB and COVID-19 symptom profiles and timing, chest imaging results, TB diagnostic testing, and hospitalizations from TB program, hospital, emergency department, and outpatient records, and from death certificates.We also obtained PCR and antigen-based COVID-19 test results, including negative results, beginning on March 9, 2020.We performed statistical comparisons by using 2-sided χ 2 or Fisher exact tests for categorical data and Wilcoxon 2-sample tests for continuous data (α = 0.05) (Appendix).Among 58 patients with COVID-19 and TB, 51 had pulmonary or pleural TB disease.The median time from symptom onset to TB diagnosis was 29.0

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.